[
  {
    "ts": "2025-06-23T09:35:29+00:00",
    "headline": "Vertex presents data from Phase I/II stage of trial for type 1 diabetes",
    "summary": "The safety profile of the therapy was found to be favourable, without any serious adverse events linked to the treatment.",
    "url": "https://www.clinicaltrialsarena.com/news/vertex-phase-i-ii-trial/",
    "source": "Clinical Trials Arena",
    "provider": "yfinance",
    "raw": {
      "id": "b1e6dded-8c07-3e7b-a2b0-44ddf547dd9e",
      "content": {
        "id": "b1e6dded-8c07-3e7b-a2b0-44ddf547dd9e",
        "contentType": "STORY",
        "title": "Vertex presents data from Phase I/II stage of trial for type 1 diabetes",
        "description": "",
        "summary": "The safety profile of the therapy was found to be favourable, without any serious adverse events linked to the treatment.",
        "pubDate": "2025-06-23T09:35:29Z",
        "displayTime": "2025-06-23T09:35:29Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Clinical Trials Arena",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.clinicaltrialsarena.com/news/vertex-phase-i-ii-trial/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-presents-data-phase-ii-093529489.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-06-23T08:00:00+00:00",
    "headline": "Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea",
    "summary": "BOSTON & OSAKA, Japan, June 23, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept in Japan and South Korea. Povetacicept is a recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines with best-in-class potential bein",
    "url": "https://finance.yahoo.com/news/vertex-ono-pharmaceutical-announce-strategic-080000941.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "04fe429a-60b8-3c88-a0de-e3f3072085d7",
      "content": {
        "id": "04fe429a-60b8-3c88-a0de-e3f3072085d7",
        "contentType": "STORY",
        "title": "Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea",
        "description": "",
        "summary": "BOSTON & OSAKA, Japan, June 23, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Ono Pharmaceutical Co., Ltd. (OTCMKTS: OPHLY) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept in Japan and South Korea. Povetacicept is a recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines with best-in-class potential bein",
        "pubDate": "2025-06-23T08:00:00Z",
        "displayTime": "2025-06-23T08:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/69d3a816d97dbd34069cdee010c18897",
          "originalWidth": 480,
          "originalHeight": 252,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dQceO4tJkm_3j9kJE4Q_nQ--~B/aD0yNTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/69d3a816d97dbd34069cdee010c18897.cf.webp",
              "width": 480,
              "height": 252,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7V2qOTDbmfpyHh0bBDdW8Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/69d3a816d97dbd34069cdee010c18897.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-ono-pharmaceutical-announce-strategic-080000941.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-ono-pharmaceutical-announce-strategic-080000941.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "OPHLF"
            },
            {
              "symbol": "OPHLY"
            },
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]